Skip to Content

Posts tagged with "Patents and IP"

  • Drug Prices

    Generics Get Cheaper, As They Should

    Here’s a useful perspective from Alex Tabarrok at Marginal Revolution: several recent studies have concluded that, over the last several years, generic drug prices as a whole have continued to decrease. That’s how it’s supposed to be: all those prescription drugs whose prices seem ridiculous are (eventually) doomed. They’ll… Read More
  • Drug Prices

    The AG of Massachusetts Has No Chance Against Gilead

    Drug prices too high? Why not just have the state Attorney General’s office set them for you? That’s what I’m taking away from this story. Maura Healy, AG of Massachusetts, is firing a warning shot at Gilead over the pricing of their HepC drugs. Her office is apparently considering whether Gilead is engaging in an… Read More
  • Biological News

    Why This CRISPR Article, and Why Now?

    I mentioned the CRISPR patent fight here the other day, but that’s not the only front where conflict has broken out. Cell has published a piece by Eric Lander called “The Heroes of CRISPR” that’s attracting some controversy, for example. The problem is that Lander (at the Broad Institute) is unlikely to be a completely… Read More
  • Biological News

    The CRISPR Interference Case

    Now this is going to be a complicated process indeed: the CRISPR patent dispute is now officially an interference proceeding at the USPTO. This was always a likely path – the main other one would have been for the parties involved to have negotiated some sort of cross-licensing agreement, but that doesn’t seem to be… Read More
  • Patents and IP

    How Do You Find A New Compound to Patent?

    I recently had a question from an interested reader, who’s outside of medicinal chemistry, wondering about how we find room to work in patent space. From his viewpoint, there seemed to be many areas that were so worked over that he found it had to see how any new project could make headway, or be… Read More
  • Patents and IP

    The Problem With Patents

    Fair warning: this is a post about patents and IP. I say that because in the past, I’ve practically been able to see the readers fleeing in real time when such things come up. Two or three of them in a row, and there would probably be nobody left around at all. But it’s a… Read More
  • Business and Markets

    Alnylam Sues Dicerna

    Here’s the latest RNAi dustup: Alnylam has filed a “trade secret misappropriation” lawsuit against Dicerna (thanks to a commenter here for mentioning this news). The real issue seems to be use of GalNAc conjugates for delivering siRNAs to the liver. Alnylam’s president, Barry Greene says that “Alnylam has led the disco… Read More
  • Business and Markets

    Nice Patent You Have There. . .

    This does not seem to me like a great advance in intellectual property law: this Bloomberg article says that some large investors are using the patent challenge process for their own purposes: Taking advantage of new rules created by Congress three years ago, hedge funds have increasingly been filing challenges to pharmaceutical patents. Some may… Read More
  • Business and Markets

    Merck, Cubist, and Hospira: The Inside

    Or as much of the inside as we’re likely to have. Thanks to @AndyBiotech on Twitter, here’s an SEC document detailing the negotiations between Merck and Cubist. It makes for interesting reading in general – you can see how a deal like this comes together, and all the places where it might have fallen apart… Read More
  • Biological News

    Who Owns CRISPR?

    Update: see also this post at Xconomy for a look at this issue. CRISPR/Cas9 is an excellent technique for gene manipulation. Its discovery is absolutely going to be the subject of a Nobel prize; I think it’s pretty much of a lock. But at the moment, there’s a vicious legal fight going on over who… Read More
123...